Results 51 to 60 of about 12,640 (186)

Aphasic status epilepticus due to Epstein–Barr virus meningoencephalitis – A clinical vignette

Epileptic Disorders, EarlyView.
Gemma Bassani, Tobias Moser, Lukas Machegger, Fabio Rossini, Georg Pilz, Eugen Trinka, Giorgi Kuchukhidze   +6 more
wiley   +1 more source

Novel approaches for drug development against chronic primary pain: A systematic review

British Journal of Pharmacology, EarlyView.
Abstract Chronic primary pain (CPP) persisting for more than 3 months, associated with significant emotional distress without any known underlying cause, is an unmet medical need. Traditional or adjuvant analgesics do not provide satisfactory pain relief for a great proportion of these patients.
Valéria Tékus, Éva Borbély, Andreas Goebel, Ralf Baron, Zsófia Hajna, Zsuzsanna Helyes   +5 more
wiley   +1 more source

Preparation, in vitro and ex-vivo Evaluation of Mirtazapine Nanosuspension and Nanoparticles Incorporated in Orodispersible Tablets

Iraqi Journal of Pharmaceutical Sciences, 2020
The objective of the present investigation was to enhance the solubility of practically insoluble mirtazapine by preparing nanosuspension, prepared by using solvent anti solvent technology.
Hiba E. Hamed, Ahmed A. Hussein
doaj   +1 more source

Mirtazapin [PDF]

pharma-kritik, 2000
N ...
openaire   +1 more source

In silico prediction of novel effective combinational treatment of chronic pain in individual patients: A joint white paper of the H2020 QSPainRelief consortium

British Journal of Pharmacology, EarlyView.
Abstract Opioids are prescribed widely for chronic pain despite well‐recognised risks and variable long‐term benefit, reflecting the lack of effective alternatives for many patients. Combination therapies offer a promising strategy to enhance efficacy whilst reducing side effects.
André Mouraux, Solenn Gousset, Beltrán Alvarez, Monica Baiula, Wouter Bakker, Andrea Bedini, Monir Bertayli, Divakar Budda, Robert Carr, Elisabetta Cuna, Óscar Díaz, Nina Donner, Jesús Giraldo, Geert‐Jan Groeneveld, Berfin Gülave, David Guydan, Hemme Hijma, Rafael Maldonado, Pedro Renault, Carlos Rinaudo, Jeroen Elaissaiss‐Schaap, Athan Spiros, Sara Stoeber, Petri Takkala, Daan van Valkengoed, Coen van Hasselt, Elizabeth (Liesbeth) CM de Lange   +26 more
wiley   +1 more source

Current Approaches to Support Patients to Withdraw From Image and Performance Enhancing Drugs

Clinical Endocrinology, EarlyView.
ABSTRACT Image and performance‐enhancing drugs (IPEDs) include agents such as androgens, growth hormone, and erythropoietin, which are used to enhance appearance and physical performance. Androgens, also known as anabolic‐androgenic steroids (AAS), are the most used IPEDs worldwide.
Elizabeth Hyams, Bonnie Grant, Richard Quinton, Channa N. Jayasena   +3 more
wiley   +1 more source

A monoarthritis case following mirtazapine use

Psychiatry and Clinical Psychopharmacology, 2021
Mirtazapine is an antidepressant drug affecting both noradrenergic and serotonergic systems with a primary use in the treatment of depression. In this report, a patient who developed monoarthritis following mirtazapine treatment with a daily dose of 30 ...
Hatice Güz, Ayhan Bilgici, Ayşin Mutlu Tomaç   +2 more
doaj  

Mirtazapine decreased cocaine-induced c-fos expression and dopamine release in rats

Frontiers in Psychiatry
IntroductionChronic cocaine exposure induces an increase in dopamine release and an increase in the expression of the Fos protein in the rat striatum.
Susana Barbosa-Méndez, Alberto Salazar-Juárez   +1 more
doaj   +1 more source

Mental Health Disorders in End‐Stage Kidney Disease: A Narrative Review of Clinical Considerations for Integrated Management

Hemodialysis International, EarlyView.
ABSTRACT Introduction End stage kidney disease (ESKD) is associated with a high prevalence of depression and anxiety, arising from both biological factors and the psychosocial burden of chronic dialysis care. Approximately 25%–30% of dialysis patients experience clinically significant depressive symptoms when assessed by structured clinical interview ...
Kunal Malhotra, Jordan Fangue‐Nelon, Garima Singh   +2 more
wiley   +1 more source

THE COMPARISON OF AMITRIPTYLINE AND MIRTAZAPINE SIDE EFFECTS ON DEPRESSION TREATMENT

Psychiatry and Clinical Psychopharmacology, 2021
Objective: In this study, the efficacy of amitriptyline and mirtazapine on depression and anxiety concomitant with depression and their side effects were compared.
Ramazan Özcankaya, Abdurahman Acar
doaj